Status:
COMPLETED
Acceptability of Less Harmful Alternatives to Cigarettes
Lead Sponsor:
Roswell Park Cancer Institute
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Bladder Cancer
Cervical Cancer
Eligibility:
All Genders
18-120 years
Phase:
NA
Brief Summary
RATIONALE: A study that evaluates participants' beliefs about smokeless tobacco products and nicotine replacement therapy may be useful in helping smokers stop smoking. PURPOSE: This clinical trial i...
Detailed Description
OBJECTIVES: Primary * To assess the impact of factual information (a fact sheet) about the relative harms of smokeless (SL)/nicotine replacement (NR) products on participants' beliefs about relative...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Currently smokes ≥ 10 cigarettes per day
- Not planning to quit smoking in the next 30 days and has not tried to quit in the past 30 days
- Medically eligible to receive nicotine-replacement products, based on the NYS Smokers Quitline eligibility criteria
- PATIENT CHARACTERISTICS:
- Not pregnant or nursing
- Able to read and speak English
- In good general health
- No history of heart attack or stroke in the past 2 weeks
- No history of chest pains in the past month
- No report of physician-diagnosed arrhythmia/irregular heartbeat or use of pacemaker
- No report of physician-diagnosed heart disease/coronary artery disease, uncontrolled hypertension, stomach ulcer, diabetes, depression, or asthma
- PRIOR CONCURRENT THERAPY:
- No other concurrent tobacco products or nicotine medications
- No concurrent Zyban, Bupropion, Wellbutrin, Chantix, or other smoking cessation medication
Exclusion
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT00957424
Start Date
June 1 2009
End Date
November 1 2011
Last Update
February 7 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263-0001